ViiV Aims To Extend HIV Drug Durations With Halozyme’s Technology

Duo Will Expand Body’s Intake Capacity For Injected Medicines

 
• By Sten Stovall
  
ViiV has licensed Halozyme’s platform globally for specific HIV targets • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business